Quintiles IMS Holdings has completed its previously announced merger between IMS Health Holdings, a pharmaceutical market information and technology provider, and Quintiles Transnational Holdings, a contract research organization. The companies agreed to merge in an all-stock merger of equals transaction in a deal valued at approximately $8.75 billion. The newly merged company has been named Quintiles IMS Holdings.

Under the merger agreement, IMS Health shareholders received a fixed exchange ratio of 0.384 shares of Quintiles common stock for each share of IMS Health common stock. Upon completion of the merger, IMS Health shareholders own approximately 51.4% of the shares of the combined company on a fully diluted basis, and Quintiles shareholders own approximately 48.6% of the combined company on a fully diluted basis.

The combined company expects to maintain dual headquarters in Danbury, Connecticut and Research Triangle Park, North Carolina. Senior functional leaders reporting to chairman and chief executive officer, Ari Bousbib, will include Michael McDonnell, executive vice president (EVP) and chief financial officer; James Erlinger, EVP and general counsel; and Trudy Stein, EVP and chief human resources officer.

Source: Quintiles IMS Holdings